metricas
covid
Buscar en
Vacunas (English Edition)
Toda la web
Inicio Vacunas (English Edition) In silico designed novel multi epitope vaccine construct towards Bundibugyo Ebol...
Journal Information
Vol. 23. Issue 3.
Pages 194-207 (September - December 2022)
Share
Share
Download PDF
More article options
Vol. 23. Issue 3.
Pages 194-207 (September - December 2022)
Original
In silico designed novel multi epitope vaccine construct towards Bundibugyo Ebolavirus
Rajaguru Arivuselvama, A. Mohamed Sheik Tharikb, S.B. Santhoshc, S.N. Meyyanathanb, Raman Rajeshkumara,
Corresponding author
a Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Tamilnadu, India
b Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Tamilnadu, India
c Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Tamilnadu, India
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (22)
Show moreShow less
Tables (1)
Table 5. Refinement of constructed vaccine.
Abstract

The aim of this research is to develop a protein-based vaccine for immunization against the Ebola virus disease (EVD) using immunological information and knowledge of structural biology. According to WHO reports the fatality rate of the EVD is around 67% in the year 2019. Particularly, the Bundibugyo Ebolaviruses has the least pathogenic fatality rate approximately around 37%. Moreover, in past outbreaks, the fatality rate is different from 25 to 95% due to a shortage of powerful medication and vaccines. In this present work, immunological information tools and databases to retrieve the highest antigenicity of B-cell and T-cell epitopes from Ebola virus (EBOV) glycoprotein. Vaccine was constructed using 5CD8+, 8CD4+, and 6B-cell epitope with suitable linkers. Mycobacterium tuberculosis lipoprotein has been introduced into the vaccine as an adjuvant to strengthen the vaccine's efficacy. Physicochemical properties of the developed vaccine were assessed, which incorporates solubility, stability, and so forth. The interactions between the vaccine and Toll-like receptors 3, 4, and 7, have been studied. The constructed vaccine demonstrates enhanced cellular immunity and also assesses the clearance of antigen from the body at various exposures.

Keywords:
Immunoinformatics
Vaccine linkers
In-silico biology
Epitope
Immunization
Ebola virus
Resumen

El objetivo de este estudio es desarrollar una vacuna a base de proteínas, para inmunización contra la enfermedad por el virus del Ébola (EVE) utilizando información inmunológica y conocimiento sobre biología estructural. En virtud de los informes de la OMS, la tasa de fatalidad de EVE se situó cerca del 67% en el año 2019. En particular, el virus Bundibugyo, tiene la menor tasa de fatalidad patogénica, de aproximadamente el 37%. Además, en los brotes pasados la tasa de fatalidad pasó del 25 al 95%, debido a la escasez de fármacos potentes y vacunas. En este trabajo se han utilizado herramientas de información y bases de datos inmunológicos para obtener la mayor antigenicidad de los epítopes de células B y células T de la glucoproteína del virus del Ébola (EBOV). La vacuna fue construida utilizando los epítopes celulares 5CD8+, 8CD4+, y 6B con los enlaces adecuados. Se introdujo en la vacuna lipoproteína de Mycobacterium tuberculosis como adyuvante para reforzar la eficacia de la misma. Se evaluaron las propiedades fisicoquímicas de la vacuna desarrollada, que incorporan solubilidad, estabilidad, etc. Se estudiaron las interacciones entre la vacuna y los receptores de tipo Toll 3, 4 y 7. La vacuna elaborada demuestra la mejora de la inmunidad celular, y evalúa también el aclaramiento del antígeno del cuerpo a diversas exposiciones.

Palabras clave:
Inmunoinformática
Enlaces de la vacuna
Biología in-silico
Epítope
Inmunización
Virus del Ébola

Article

These are the options to access the full texts of the publication Vacunas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Vacunas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos